Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1981 1
1982 1
1984 3
1985 1
1986 2
1987 3
1988 3
1989 1
1990 5
1991 6
1992 2
1993 7
1994 14
1995 8
1996 10
1997 7
1998 18
1999 14
2000 24
2001 23
2002 28
2003 35
2004 55
2005 81
2006 103
2007 129
2008 139
2009 154
2010 160
2011 179
2012 214
2013 286
2014 276
2015 360
2016 374
2017 375
2018 387
2019 506
2020 578
2021 751
2022 441
Text availability
Article attribute
Article type
Publication date

Search Results

5,148 results
Results by year
Filters applied: . Clear all
Page 1
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Tilly H, et al. Among authors: yan m. N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14. N Engl J Med. 2022. PMID: 34904799 Clinical Trial.
Interaction between macrophages and ferroptosis.
Yang Y, Wang Y, Guo L, Gao W, Tang TL, Yan M. Yang Y, et al. Among authors: yan m. Cell Death Dis. 2022 Apr 16;13(4):355. doi: 10.1038/s41419-022-04775-z. Cell Death Dis. 2022. PMID: 35429990 Free PMC article. Review.
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.
Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, Sun T, Teng Y, Wu X, Ouyang Q, Yan X, Cheng J, Liu Q, Feng J, Wang X, Yin Y, Shi Y, Pan Y, Wang Y, Xie W, Yan M, Liu Y, Yan P, Wu F, Zhu X, Zou J; DAWNA-1 Study Consortium. Xu B, et al. Among authors: yan m. Nat Med. 2021 Nov;27(11):1904-1909. doi: 10.1038/s41591-021-01562-9. Epub 2021 Nov 4. Nat Med. 2021. PMID: 34737452 Clinical Trial.
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.
Zhang J, Ji D, Cai L, Yao H, Yan M, Wang X, Shen W, Du Y, Pang H, Lai X, Zeng H, Huang J, Sun Y, Peng X, Xu J, Yang J, Yang F, Xu T, Hu X. Zhang J, et al. Among authors: yan m. Clin Cancer Res. 2022 Feb 15;28(4):618-628. doi: 10.1158/1078-0432.CCR-21-2827. Clin Cancer Res. 2022. PMID: 34844975 Clinical Trial.
5,148 results